The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Result of General Meeting

11 Jul 2018 10:38

RNS Number : 3108U
Adamas Finance Asia Limited
11 July 2018
 

ADAMAS FINANCE ASIA LIMITED

 

RESULT OF GENERAL MEETING

APPROVAL OF DISPOSAL OF GLOBAL PHARM INTEREST

 

Further to the announcement on 15 June 2018 in relation to the proposed disposal of the interest in Global Pharm, the Company is pleased to announce that the resolutions proposed at the General Meeting held earlier today were duly passed and that the Disposal has thereby been approved.

Completion of the Disposal and the associated issue of 17,746,479 new Ordinary Shares at a price of US$0.71 per share to Fortune Insight Limited will take place in due course.

A further announcement will be made when appropriate.

Capitalised terms used in this announcement have the meaning given to them in the announcement of 15 June 2018.

 

Enquiries:

Adamas Finance Asia Limited

John Croft

 

+44 (0)1825 830587

Nominated Adviser

 

WH Ireland Limited

Tim Feather

James Sinclair-Ford

+44 (0) 113 394 6600

Broker

 

Shard Capital Partners LLP

 

Philip Pooley

 

 

+44 (0) 20 7186 9967

Public Relations Advisers

 

Buchanan

Charles Ryland

Henry Wilson

+44 (0) 20 7466 5000

 

 About Adamas Finance Asia ("ADAM")

ADAM is a London quoted investment company focusing on delivering long-term income and capital growth to shareholders through a diverse portfolio of pan-Asian investments. It aims to provide uncorrelated returns through a combination of capital growth and dividend income from a broad spectrum of national geographies and asset classes.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMKFLBFVDFXBBQ

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.